Cited 7 times in
Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 김자경 | - |
dc.contributor.author | 김현숙 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2017-10-26T07:45:38Z | - |
dc.date.available | 2017-10-26T07:45:38Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/152482 | - |
dc.description.abstract | Hepatitis C virus core antigen (HCV Ag) is a recently developed marker of hepatitis C virus (HCV) infection. We investigated the clinical utility of the new HCV Ag assay for prediction of treatment response in HCV infection. We analyzed serum from 92 patients with HCV infection who had been treated with pegylated interferon and ribavirin. HCV Ag levels were determined at baseline in all enrolled patients and at week 4 in 15 patients. Baseline HCV Ag levels showed good correlations with HCV RNA (r = 0.79, P < 0.001). Mean HCV Ag levels at baseline were significantly lower in patients with a sustained virologic response (SVR) than in those with a non SVR (relapse plus non responder) based on HCV RNA analysis (2.8 log₁?fmol/L vs. 3.27 log₁?fmol/L, P = 0.023). Monitoring of the viral kinetics by determination of HCV RNA and HCV Ag levels resulted in similarly shaped curves. Patients with undetectable HCV Ag levels at week 4 had a 92.3% probability of achieving SVR based on HCV RNA assay results. The HCV Ag assay may be used as a supplement for predicting treatment response in HCV infection, but not as an alternative to the HCV RNA assay. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | 대한의학회(The Korean Academy of Medical Sciences) | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antigens, Viral/blood* | - |
dc.subject.MESH | Antiviral Agents/therapeutic use | - |
dc.subject.MESH | Automation | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Hepacivirus/genetics* | - |
dc.subject.MESH | Hepacivirus/isolation & purification | - |
dc.subject.MESH | Hepacivirus/metabolism | - |
dc.subject.MESH | Hepatitis C, Chronic/drug therapy | - |
dc.subject.MESH | Hepatitis C, Chronic/virology* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoassay | - |
dc.subject.MESH | Interferon-alpha/therapeutic use | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Polyethylene Glycols/therapeutic use | - |
dc.subject.MESH | Polymerase Chain Reaction | - |
dc.subject.MESH | RNA, Viral/blood* | - |
dc.subject.MESH | Reagent Kits, Diagnostic | - |
dc.subject.MESH | Recombinant Proteins/therapeutic use | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Ribavirin/therapeutic use | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C | - |
dc.type | Article | - |
dc.publisher.location | Korea (South) | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Mi Na Kim | - |
dc.contributor.googleauthor | Hyon-Suk Kim | - |
dc.contributor.googleauthor | Ja Kyung Kim | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.identifier.doi | 10.3346/jkms.2016.31.9.1431 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A00852 | - |
dc.contributor.localId | A01117 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J01517 | - |
dc.identifier.eissn | 1598-6357 | - |
dc.identifier.pmid | 27510387 | - |
dc.subject.keyword | Chronic Hepatitis C | - |
dc.subject.keyword | HCV Core Antigen | - |
dc.subject.keyword | HCV RNA | - |
dc.subject.keyword | Treatment Response | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Kim, Ja Kyung | - |
dc.contributor.alternativeName | Kim, Hyon Suk | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Kim, Ja Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Hyon Suk | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.citation.volume | 31 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1431 | - |
dc.citation.endPage | 1437 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.31(9) : 1431-1437, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 48685 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.